TRANSLATE

The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

How should duration of response be defined?

Featured:

Mohamad MohtyMohamad MohtyAli BazarbachiAli BazarbachiAttilio OlivieriAttilio OlivieriAmin AlousiAmin AlousiHildegard GreinixHildegard Greinix

Jul 22, 2022

Learning objective: After listening to this discussion, learners will be able to cite how to define response in GvHD.


During the GvHD Hub Steering Committee meeting on April 5, 2022, key opinion leaders met to debate how duration of response should be defined. The recorded discussion was chaired by Mohamad Mohty and featured Amin Alousi, Ali Bazarbachi, Hildegard Greinix, and Attilio Olivieri.

How should duration of response be defined?

Mohty begins by stating that it is only recently, with the approval of agents for GvHD treatment, that the question of how to define response has become a concern. Bazarbachi discusses the importance of achieving an ongoing response rather than a transient one to improve outcomes in acute GvHD. The steering committee contemplate how the side effects of treatment can result in early initiation of the next line of therapy, and the impact of organ damage on response definition is also considered.